Redwood Scientific Technologies Inc. (OTC: RSCI) ("Redwood" or "the Company"), a pharmaceutical company, today announced a strategic shift in its product development priorities

Rhea-AI Summary

Redwood Scientific Technologies Inc. (OTC: RSCI) announced a strategic shift in product development to focus on enhancing nicotine replacement therapy products TBX-FREE™ and TBX VAPE-FREE™. This decision follows research linking e-cigarette use to heart failure risks, emphasizing the need for safer alternatives.

NEW YORK, April 18, 2024 /PRNewswire/ -- Redwood Scientific Technologies Inc. (OTC: RSCI) ("Redwood" or "the Company"), a pharmaceutical company, today announced a strategic shift in its product development priorities. The New York-based firm will only focus on enhancing and expanding its nicotine replacement therapy (NRT) products, specifically TBX-FREE™ and TBX VAPE-FREE™.

This pivotal decision follows recent findings published by the American College of Cardiology, sourced from a study conducted by the National Institute of Health. The study highlights a significant correlation between e-cigarette use and an increased risk of heart failure, underscoring the urgency for effective and safe alternatives in nicotine replacement therapy.

"Given the alarming data linking e-cigarette use to serious health risks, Redwood is committed to advancing our development of TBX-FREE™ and TBX VAPE-FREE™ products," said Jason Cardiff,  CEO of Redwood Scientific Technologies. "Our goal is clear – to provide safer, scientifically-backed alternatives that meet the needs of consumers aiming to quit smoking without the harmful effects associated with e-cigarettes."

Redwood believes that its TBX-FREE™ and TBX VAPE-FREE™ products will be innovative solutions in the realm of nicotine replacement therapy. The company anticipates publication of double blind randomized studies before bringing these products to market.

By concentrating its resources on TBX-FREE™ and TBX VAPE-FREE™, Redwood is positioning itself to be at the forefront of a critical market, responding proactively to the latest scientific research and public health needs.

For more information about Redwood Scientific Technologies and its products, please visit www.Redwoodsci.com

About Redwood Scientific Technologies Inc.

Redwood Scientific Technologies Inc. (OTC: RSCI) is a pharmaceutical company dedicated to developing innovative drug delivery systems. Based in New York, Redwood aims to enhance the efficacy and accessibility of pharmaceutical therapies to improve patient outcomes and quality of life.

Contact:
Name: Public Relations
Title: Communications
Email: info@redwoodsci.com
Phone: (123) 456-7890

View original content to download multimedia:https://www.prnewswire.com/news-releases/redwood-scientific-technologies-inc-otc-rsci-redwood-or-the-company-a-pharmaceutical-company-today-announced-a-strategic-shift-in-its-product-development-priorities-302120397.html

SOURCE REDWOOD SCIENTIFIC TECHNOLOGIES

FAQ

What did Redwood Scientific Technologies Inc. announce regarding its product development priorities?

Redwood announced a strategic shift to focus on enhancing and expanding its nicotine replacement therapy products TBX-FREE™ and TBX VAPE-FREE™.

What recent findings influenced Redwood's decision to focus on nicotine replacement therapy products?

Recent findings from a study conducted by the National Institute of Health, published by the American College of Cardiology, linking e-cigarette use to an increased risk of heart failure influenced Redwood's decision.

Who is the CEO of Redwood Scientific Technologies Inc.?

Jason Cardiff is the CEO of Redwood Scientific Technologies Inc.

What is the goal of Redwood in developing TBX-FREE™ and TBX VAPE-FREE™ products?

The goal is to provide safer, scientifically-backed alternatives for consumers aiming to quit smoking without the harmful effects associated with e-cigarettes.

What type of studies does Redwood plan to publish before bringing TBX-FREE™ and TBX VAPE-FREE™ products to market?

Redwood plans to publish double blind randomized studies before bringing these products to market.